Business Context and Reporting Period
Company: Disc Medicine, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 25, 2026
Event: Entry into a Material Definitive Agreement (First Amendment to Loan Agreement) with Hercules Capital, Inc.
Key Financial Metrics and Debt Structure
This filing details a restructuring of the Company's existing credit facility rather than reporting operational financial results (revenue, profit, or cash flow). Key debt metrics disclosed include:
- Immediate Drawdown: The Company agreed to draw down $30,000,000 of the Tranche 1-B Advance.
- Tranche 1-C Restructuring: The existing $50,000,000 Tranche 1-C Advance was divided into:
- $25,000,000 available at the Company's option through March 31, 2027.
- $25,000,000 designated as a new Tranche 1-D Advance available through April 30, 2027.
- Extended Drawdown Periods:
- Tranche 2 Advance extended to December 15, 2027.
- Tranche 3 Advance extended to June 30, 2028.
- Covenant Modification: The minimum cash covenant initial testing date was amended to July 1, 2028.
Note: The filing text does not provide clear values for revenue, net income, operating cash flow, or total liquidity position outside of the specific loan terms described above.
Material Changes Versus Prior Period
The primary material change is the extension of the availability periods for future loan advances and the restructuring of the Tranche 1-C facility. Previously, the Tranche 1-C Advance was a single $50,000,000 facility; it is now split into two tranches with staggered maturity dates in 2027. Additionally, the timeline for drawing down Tranches 2 and 3 has been pushed back by approximately 12 to 18 months compared to the original agreement dated November 6, 2024.
Guidance, Outlook, and Risks
Management Commentary: The amendment was executed to extend the periods during which future advances may be drawn down, providing the Company with additional time to utilize its credit facility.
Risks and Contingencies: The Company remains subject to the minimum cash covenant, though the initial testing date has been deferred to July 1, 2028. The full text of the Amendment, containing all specific terms and conditions, is referenced as an exhibit to the upcoming Form 10-Q for the quarter ended June 30, 2026.
Investor Verification Checklist
- Verify the total outstanding debt balance immediately following the $30,000,000 Tranche 1-B drawdown.
- Review the upcoming Form 10-Q (due for the quarter ended June 30, 2026) for the full text of the Amendment and any other modifications to the Loan Agreement.
- Confirm the Company's current cash position to ensure compliance with the deferred minimum cash covenant testing date of July 1, 2028.
- Assess the impact of the extended drawdown periods on the Company's capital deployment strategy and runway.